Suppr超能文献

诺卡氏角膜炎:临床病程和皮质类固醇的作用。

Nocardia keratitis: clinical course and effect of corticosteroids.

机构信息

Aravind Eye Care System, Madurai, India.

出版信息

Am J Ophthalmol. 2012 Dec;154(6):934-939.e1. doi: 10.1016/j.ajo.2012.06.001. Epub 2012 Sep 5.

Abstract

PURPOSE

To compare the clinical course of Nocardia species keratitis with keratitis resulting from other bacterial organisms and to assess the effect of corticosteroids as adjunctive therapy using data collected from the Steroids for Corneal Ulcers Trial.

DESIGN

Subgroup analysis of a randomized controlled trial.

METHODS

setting: Multicenter randomized controlled trial. study population: Five hundred patients with bacterial keratitis randomized 1:1 to topical corticosteroid or placebo who had received at least 48 hours of topical moxifloxacin. intervention/observation procedure: Topical prednisolone phosphate 1% or placebo and clinical course of Nocardia keratitis. main outcome measures: Best spectacle-corrected visual acuity and infiltrate or scar size at 3 months from enrollment.

RESULTS

Of 500 patients enrolled in the trial, 55 (11%) had a Nocardia corneal ulcer. Patients with Nocardia ulcers had better presentation visual acuity compared with non-Nocardia ulcers (median Snellen visual acuity, 20/45, compared with 20/145; P < .001) and comparable 3-month visual acuity (median, 20/25, vs 20/40; P = .25). Nocardia ulcers had approximately 2 lines less of improvement in visual acuity compared with non-Nocardia ulcers (0.21 logarithm of the minimal angle of resolution; 95% confidence interval, 0.09 to 0.33 logarithm of the minimal angle of resolution; P = .001). This difference may reflect the better starting visual acuity in patients with Nocardia ulcers. In Nocardia ulcers, corticosteroids were associated with an average 0.4-mm increase in 3-month infiltrate or scar size (95% confidence interval, 0.03 to 0.77 mm; P = .03).

CONCLUSIONS

Nocardia ulcers responded well to treatment. They showed less overall improvement in visual acuity than non-Nocardia ulcers, but had better presentation acuity. Corticosteroids may be associated with worse outcomes.

摘要

目的

比较诺卡氏菌角膜炎与其他细菌性角膜炎的临床病程,并利用类固醇治疗角膜溃疡试验(Steroids for Corneal Ulcers Trial)的数据评估皮质类固醇作为辅助治疗的效果。

设计

随机对照试验的亚组分析。

方法

研究场所:多中心随机对照试验。研究人群:500 例细菌性角膜炎患者按 1:1 比例随机分为局部皮质类固醇或安慰剂组,所有患者均接受了至少 48 小时的局部莫西沙星治疗。干预/观察程序:局部磷酸泼尼松龙 1%或安慰剂和诺卡氏菌角膜炎的临床病程。主要观察指标:入组后 3 个月时最佳矫正视力和浸润或瘢痕大小。

结果

在该试验中纳入的 500 例患者中,有 55 例(11%)患有诺卡氏菌角膜溃疡。与非诺卡氏菌溃疡相比,诺卡氏菌溃疡患者的就诊视力更好(中位数斯耐伦视力,20/45,对比 20/145;P<.001),且 3 个月时的视力相当(中位数,20/25,对比 20/40;P=.25)。与非诺卡氏菌溃疡相比,诺卡氏菌溃疡患者的视力改善约少 2 行(最小分辨角对数视力的 0.21;95%置信区间,0.09 至 0.33 对数最小分辨角视力;P=.001)。这种差异可能反映了诺卡氏菌溃疡患者更好的初始视力。在诺卡氏菌溃疡中,皮质类固醇与 3 个月时浸润或瘢痕大小平均增加 0.4mm(95%置信区间,0.03 至 0.77mm;P=.03)有关。

结论

诺卡氏菌溃疡对治疗反应良好。与非诺卡氏菌溃疡相比,它们的整体视力改善程度较低,但就诊时视力较好。皮质类固醇可能与较差的结果有关。

相似文献

1
Nocardia keratitis: clinical course and effect of corticosteroids.
Am J Ophthalmol. 2012 Dec;154(6):934-939.e1. doi: 10.1016/j.ajo.2012.06.001. Epub 2012 Sep 5.
2
The steroids for corneal ulcers trial (SCUT): secondary 12-month clinical outcomes of a randomized controlled trial.
Am J Ophthalmol. 2014 Feb;157(2):327-333.e3. doi: 10.1016/j.ajo.2013.09.025. Epub 2013 Oct 1.
3
Corticosteroids for bacterial keratitis: the Steroids for Corneal Ulcers Trial (SCUT).
Arch Ophthalmol. 2012 Feb;130(2):143-50. doi: 10.1001/archophthalmol.2011.315. Epub 2011 Oct 10.
4
The steroids for corneal ulcers trial: study design and baseline characteristics.
Arch Ophthalmol. 2012 Feb;130(2):151-7. doi: 10.1001/archophthalmol.2011.303. Epub 2011 Oct 10.
5
Pseudomonas aeruginosa keratitis: outcomes and response to corticosteroid treatment.
Invest Ophthalmol Vis Sci. 2012 Jan 25;53(1):267-72. doi: 10.1167/iovs.11-7840.
6
Early addition of topical corticosteroids in the treatment of bacterial keratitis.
JAMA Ophthalmol. 2014 Jun;132(6):737-41. doi: 10.1001/jamaophthalmol.2014.292.
8
Visual outcomes in treated bacterial keratitis: four years of prospective follow-up.
Invest Ophthalmol Vis Sci. 2014 May 2;55(5):2935-40. doi: 10.1167/iovs.14-13980.
9
Prior elicitation and Bayesian analysis of the Steroids for Corneal Ulcers Trial.
Ophthalmic Epidemiol. 2012 Dec;19(6):407-13. doi: 10.3109/09286586.2012.735332.
10
Association between cytotoxic and invasive Pseudomonas aeruginosa and clinical outcomes in bacterial keratitis.
JAMA Ophthalmol. 2013 Feb;131(2):147-53. doi: 10.1001/jamaophthalmol.2013.778.

引用本文的文献

1
Steroids in the Management of Infectious Keratitis.
Cornea. 2023 Nov 1;42(11):1333-1339. doi: 10.1097/ICO.0000000000003340. Epub 2023 Jul 4.
2
Nocardia infection following ocular surface surgery.
Int Ophthalmol. 2023 Mar;43(3):981-988. doi: 10.1007/s10792-022-02500-5. Epub 2022 Sep 14.
3
Nocardia keratitis: amikacin nonsusceptibility, risk factors, and treatment outcomes.
J Ophthalmic Inflamm Infect. 2022 Mar 5;12(1):11. doi: 10.1186/s12348-022-00287-1.
4
Infectious keratitis: an update on epidemiology, causative microorganisms, risk factors, and antimicrobial resistance.
Eye (Lond). 2021 Apr;35(4):1084-1101. doi: 10.1038/s41433-020-01339-3. Epub 2021 Jan 7.
5
Current diagnostic tools and management modalities of Nocardia keratitis.
J Ophthalmic Inflamm Infect. 2020 Dec 2;10(1):36. doi: 10.1186/s12348-020-00228-w.
6
Nocardiosis: A Neglected Disease.
Med Princ Pract. 2020;29(6):514-523. doi: 10.1159/000508717. Epub 2020 May 18.
7
Pulmonary Nocardia ignorata Infection in Gardener, Iran, 2017.
Emerg Infect Dis. 2020 Mar;26(3):610-611. doi: 10.3201/eid2603.180725.
8
Update on the Management of Infectious Keratitis.
Ophthalmology. 2017 Nov;124(11):1678-1689. doi: 10.1016/j.ophtha.2017.05.012. Epub 2017 Sep 21.
9
Trends in antibiotic resistance in bacterial keratitis isolates from South India.
Br J Ophthalmol. 2017 Feb;101(2):108-113. doi: 10.1136/bjophthalmol-2016-308487. Epub 2016 Apr 29.
10
Use of adjunctive topical corticosteroids in bacterial keratitis.
Curr Opin Ophthalmol. 2016 Jul;27(4):353-7. doi: 10.1097/ICU.0000000000000273.

本文引用的文献

1
Relationship of in vitro susceptibility to moxifloxacin and in vivo clinical outcome in bacterial keratitis.
Clin Infect Dis. 2012 May;54(10):1381-7. doi: 10.1093/cid/cis189. Epub 2012 Mar 23.
2
Pseudomonas aeruginosa keratitis: outcomes and response to corticosteroid treatment.
Invest Ophthalmol Vis Sci. 2012 Jan 25;53(1):267-72. doi: 10.1167/iovs.11-7840.
3
Corticosteroids for bacterial keratitis: the Steroids for Corneal Ulcers Trial (SCUT).
Arch Ophthalmol. 2012 Feb;130(2):143-50. doi: 10.1001/archophthalmol.2011.315. Epub 2011 Oct 10.
4
The steroids for corneal ulcers trial: study design and baseline characteristics.
Arch Ophthalmol. 2012 Feb;130(2):151-7. doi: 10.1001/archophthalmol.2011.303. Epub 2011 Oct 10.
5
Optimizing diagnosis and management of nocardia keratitis, scleritis, and endophthalmitis: 11-year microbial and clinical overview.
Ophthalmology. 2011 Jun;118(6):1193-200. doi: 10.1016/j.ophtha.2010.10.037. Epub 2011 Jan 26.
6
Nocardia keratitis.
Curr Opin Ophthalmol. 2009 Jul;20(4):318-23. doi: 10.1097/ICU.0b013e32832c3bcc.
7
The case against the use of steroids in the treatment of bacterial keratitis.
Arch Ophthalmol. 2009 Jan;127(1):103-4. doi: 10.1001/archophthalmol.2008.503.
8
Does in vitro susceptibility predict clinical outcome in bacterial keratitis?
Am J Ophthalmol. 2008 Mar;145(3):409-412. doi: 10.1016/j.ajo.2007.11.004. Epub 2008 Jan 22.
9
The first case of keratitis caused by Nocardia exalbida.
Int Ophthalmol. 2007 Oct;27(5):333-6. doi: 10.1007/s10792-007-9079-0. Epub 2007 May 3.
10
Nocardia keratitis: species, drug sensitivities, and clinical correlation.
Cornea. 2007 Apr;26(3):255-9. doi: 10.1097/ICO.0b013e318033d853.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验